BCM
KPTI icon

Boxer Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Boxer Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Buy
302,536
+50,000
+20% +$381K 0.22% 47
2025
Q4 		$1.86M Buy
+252,536
New +$1.54M 0.41% 37

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Boxer Capital Management's KPTI Position: Q1 2026 in Review

Boxer Capital Management increased its Karyopharm Therapeutics (KPTI) stake by 20% in Q1 2026, buying an estimated $381K and bringing the position to 302,536 shares worth $1.69M. The position accounts for 0.22% of the portfolio, ranked #47.

Boxer Capital Management first reported a position in KPTI in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.86M in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Boxer Capital Management held 302,536 shares of Karyopharm Therapeutics worth $1.69M as of Q1 2026.
  • Boxer Capital Management bought 50,000 Karyopharm Therapeutics shares in Q1 2026, an estimated $381K.
  • Karyopharm Therapeutics made up 0.22% of Boxer Capital Management's portfolio in Q1 2026, its #47 holding.
  • Boxer Capital Management first reported a position in Karyopharm Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Boxer Capital Management's Karyopharm Therapeutics position peaked at $1.86M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Boxer Capital Management's 13F filing for Q1 2026, filed 15 May 2026.